Vical researches and develops biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Our active independent and partnered development programs include:
- Infectious disease vaccines for use in high-risk populations
- Infectious disease vaccines for general pediatric, adolescent and adult populations
- Cancer vaccines or immunotherapies
- Gene-based delivery of angiogenic growth factors for treatment of cardiovascular diseases
Headquartered in San Diego, CA, Vical is driven by 115 people from some 20 different countries. Vical is independently pioneering the development of paradigm-changing DNA vaccines and cancer immunotherapies, and is partnering with such industry leaders as Merck, sanofi-aventis, Novartis, Astellas, AnGes, Merial and the NIH.